Irini Daniel, a former medical scientific liaison and business development manager at Health House International, has launched a new specialist in-person pharmacy in North Strathfield, Sydney.
Daniel said Folium Dispensary aims to "revolutionise the patient experience by offering personalised and comprehensive care, while remaining cost effective".
The pharmacy has no preferred supplier agreements, with products sourced from "whoever can supply to us at the best price so that we can keep prices at their lowest for patients", Daniel added.
Alongside medicinal cannabis, the dispensary stocks a selection of natural health products, including vitamins, herbal and nutritional supplements, and essential oils.
Complementary services such as acupuncture, aromatherapy and nutritional counselling are offered through businesses operating nearby.
Montu
Montu has appointed George Tambassis, a former national president of the Pharmacy Guild of Australia, as a special adviser.
Welcoming Tambassis to the company's advisory board, Montu managing director Christopher Strauch said he would "provide critical expertise to our business and the complex environment in which we operate".
"Adding such deep understanding and insights into the pharmacy landscape in Australia as we continue to grow and expand our business will be invaluable," Strauch said.
"We look forward to working closely with George as we push for governmental change in having medical cannabis treated the same as any other prescription medication."
Tambassis added: "I am really excited to have this chance to assist in enhancing pharmacists' knowledge of the benefits of medical cannabis.
"Through this advisory appointment, I look forward to continuing to contribute to this important work and improving accessibility, awareness and patient outcomes."
Vantage Hemp Co
Colorado-based Vantage Hemp has received Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration, covering the production of medicinal CBD extracts, isolates and finished goods.
The company said GMP certification "opens new doors for partnership opportunities". In mid-2022, it signed a deal with Medcan to import its pharmaceutical-grade CBD into Australia.
Cann Global
Cann Global has been officially delisted after repeatedly failing to submit its financial reports on time.
The ASX confirmed the decision was made because the company was more than 12 months overdue in lodging the required documents.
Should Cann Global seek to return to the exchange at a future point, it will need to lodge a fresh application with the ASX.
In a statement, the ASX said the company "failed to lodge the relevant periodic report… for a continuous period of one year after the deadline lodgement of that document".
The delisting comes 18 months after Cann Global voluntarily suspended its shares while pursuing an acquisition that has not yet been completed.
Last week, managing director Sholom Feldman said the firm was working with new auditors to finalise its outstanding financial report and told shareholders it was in the final stages of due diligence with a third party ahead of finalising the terms of a transaction.
Feldman maintained that the formal removal from the ASX had little practical impact on the company.
"There is no practical difference to us if we are suspended or delisted during this time as the ASX were asking us [to reapply] under the acquisition," he said.
InhaleRx
Inhalation drug-device company InhaleRx has named company secretary James Barrie as interim director following the board departure of Dr John Crock.
Crock, who will continue in an advisory role, is stepping down due to growing demands at his surgical practice.
Barrie will serve as director until a permanent replacement for Crock is found.
